BioAtla's Presentation at the 39th Annual Meeting
BioAtla, Inc. (NASDAQ: BCAB), a leading clinical-stage biotechnology company, is thrilled to announce a pivotal poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting. This event brings together experts and innovators in the field of cancer treatment, and it will be an excellent opportunity to showcase BioAtla's commitment to developing innovative therapies for patients facing solid tumors.
Presentation Highlights
The presentation will focus on updated results from a significant phase 1 study that explored the effects of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic. This study examined the therapeutic potential of combining evalstotug with nivolumab, a well-known checkpoint inhibitor, in treating advanced solid tumors.
This poster will be presented on Friday, November 8, 2024, at 9:00 AM CDT, in Exhibit Halls AB. BioAtla's strong collaborative network and seasoned researchers will present the findings, highlighting their efforts to push the boundaries of cancer treatment.
About BioAtla, Inc.
Founded with a mission to transform cancer care, BioAtla has established itself as a key player in the biotechnology industry. The company leverages its unique Conditionally Active Biologics (CAB) technology to engineer monoclonal and bispecific antibodies. These advancements allow for enhanced efficacy in treatments while minimizing toxicity, which is crucial for patient safety.
Innovative CAB Technology
BioAtla's CAB technology is a groundbreaking approach that aims to create more selectively targeted cancer therapies. By utilizing this technology, the company's product candidates are designed to harness the body's immune system more effectively while reducing unwanted side effects often seen in conventional treatments.
Currently, BioAtla has two promising CAB programs progressing through Phase 2 clinical testing: mecbotamab vedotin, targeting AXL for antibody-drug conjugate therapy, and ozuriftamab vedotin aimed at ROR2 targets. These treatments have the potential to significantly alter cancer treatment paradigms by providing tailored therapeutic options for patients.
Looking Forward
The upcoming SITC Annual Meeting represents a valuable moment for BioAtla to engage with industry peers and present the results of their research that could lead to major advances in cancer therapy. As the company continues to develop therapies that address critical unmet medical needs, they maintain a robust pipeline of innovative products designed to improve outcomes for patients.
Stay Updated about BioAtla
For those interested in following BioAtla's journey, a copy of the presentation materials will be available on their website following the presentation. This initiative reflects the company’s dedication to transparency and knowledge sharing within the scientific community.
Frequently Asked Questions
What is the focus of BioAtla's upcoming presentation at SITC?
BioAtla will present updated results from a phase 1 study on evalstotug (BA3071) and its combination with nivolumab for advanced solid tumors.
Where will the presentation take place?
The presentation will be held in Exhibit Halls AB at the SITC Annual Meeting on November 8, 2024.
What is the main technology BioAtla is using in its treatments?
BioAtla utilizes Conditionally Active Biologics (CAB) technology, which focuses on selectively targeting cancer with lower toxicity.
Who are the authors involved in this presentation?
The presentation will feature contributions from a team of notable researchers including Jacob Thomas and Eva Selfridge, among others.
How can I access the presentation materials after the event?
A copy of the presentation materials will be available on BioAtla's website after the presentation concludes, promoting transparency and accessibility.
